ArticleJournal of oral biology and craniofacial research
Correlation of salivary visfatin levels in obese and NON-OBESE population with periodontal status.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 8 citations in OpenAlex.
- Irisin, a promising adipomyokine, shows low levels in relation to periodontal diseases, unlike visfatin and IL-6 (case-control study).Frontiers in oral health · 2025Article
- Correlation Between Body Mass Index and Periodontitis: A Clinical and Biochemical Analysis.Cureus · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Visfatin is an inflammatory adipokine that has been linked to obesity and plays a key function in immune response modulation. It's also been proposed that it's a pro-inflammatory marker for periodontitis. Hence, the aim of the present study was to assess the salivary Visfatin levels in obese and non-obese population and correlate with the periodontal status. Materials and methods: A total of 40 individuals aged between 21 and 35 years (Group 1: n = 20, non-obese and Group 2: n = 20, obese) were enrolled in this case-control study. Clinical parameters such as periodontal probing depth (PPD) and clinical attachment level (CAL) were recorded. Body Mass Index (BMI) was recorded. Unstimulated salivary samples were collected and the samples were assayed for Visfatin using human Visfatin ELISA kit. The results were analysed using SPSS Software, Version 23.0. Unpaired t-test and Mann-Whitney Results: The salivary Visfatin level was higher in group 2 (33.1070 ± 0.81 ng/mL) as compared to group 1 (22.2310 ± 1.33 ng/mL). Moderate positive statistically significant association was found between BMI and Visfatin (r = 0.738, p = 0.000). Also when Visfatin and PPD and CAL were correlated, moderate positive statistically significant association was found (r = 0.625, p = 0.000 and r = 0.630, p = 0.000). Conclusion: The present study suggests that there exists a positive correlation between BMI and salivary Visfatin and BMI and periodontal parameters including probing depth and clinical attachment level. This illustrates that salivary Visfatin may be a potential marker for periodontal inflammation in obese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.